What Is The Current and Historic Market Size Analysis Of The Immunohistochemistry (IHC) Market?
The immunohistochemistry (ihc) market has seen considerable growth due to a variety of factors.
• In recent times, the immunohistochemistry (IHC) market has seen robust growth. The market is projected to increase from $2.58 billion in 2024 to $2.78 billion in 2025, with a compound annual growth rate (CAGR) of 8.0%. Various factors such as the acceptance in clinical practice, industry standardization, the growth of cancer research, automation in labs, and advances in clinical diagnostics have contributed to the past growth.
What Are The Predictions for The Immunohistochemistry (IHC) Market in the Coming Years?
The Immunohistochemistry (IHC) market is expected to maintain its strong growth trajectory in upcoming years.
• The market for immunohistochemistry (IHC) is projected to experience a significant increase in the coming years, expanding to $4.13 billion by 2029, with a compound annual growth rate (CAGR) of 10.4%.
This surge in the predicted period can be credited to the introduction of new participants in the market, needs in drug creation, the incorporation of biomedical research, diagnostic usages, as well as advancements in automation and digitization. The upcoming period is expected to witness trends such as multiplex IHC procedures, the merging of digital pathology, improved antibody specificity, automation and its standardization, and its utilization in biomarker discovery.
Which Drivers Are Accelerating Growth In The Immunohistochemistry IHC Market?
The immunohistochemistry (IHC) market is projected to grow due to the escalating occurrence of chronic illnesses. Chronic ailments are medical conditions that typically last for at least three months and can typically be managed but not completely cured. Immunohistochemistry proves beneficial in diagnosing such diseases including cancer, cardiovascular conditions, and others due to its distinct features like sensitivity, specificity (to determine unique antigens), swift results, and more. For instance, data from the Centers for Disease Control and Prevention, a national public health agency in the US, reveals that approximately 37.3 million people, accounting for 11.3% of the US population, had diabetes in 2022. Thus, the rising prevalence of chronic diseases is fueling the expansion of the immunohistochemistry (IHC) market.
What Are The Core Segments Of The Global Immunohistochemistry IHC Market?
The immunohistochemistry (IHC) market covered in this report is segmented –
1) By Product: Antibodies, Equipment, Reagents, Kits
2) By Applications: Diagnostics, Drug Testing, Other Applications
3) By End-Users: Hospitals And Diagnostic Laboratories, Research Institutes, Other End-Users
Subsegments:
1) By Antibodies: Primary Antibodies, Secondary Antibodies, Conjugated Antibodies
2) By Equipment: IHC Staining Systems, Tissue Processors, Slide Scanners, Microscopes
3) By Reagents: Detection Reagents, Blocking Reagents, Mounting Media
4) By Kits: Pre-prepared IHC Kits, Multiplex IHC Kits, Specialty Kits
Pre-Book The Immunohistochemistry IHC Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Emerging Trends Are Reshaping The Immunohistochemistry IHC Market Size?
In the immunohistochemistry (IHC) market, leading firms are emphasizing innovation and the use of high-quality reagents to improve diagnostic precision and tissue analysis effectiveness in diverse clinical and research settings. The advanced Neoflex multiomics mass spectrometry imaging (MSI) system is a bespoke imaging platform, developed for accurate tissue analysis, aiding researchers in moving from discovery to practical clinical applications with precise mass spectrometry techniques, especially important for spatially mapping biomolecules in tissues. For example, in June 2024, Bruker Corporation, a US company specializing in the development and manufacturing of scientific instruments and analytical and diagnostic solutions, introduced its Neoflex Imaging Profiler, a matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF/TOF) device for tissue imaging through mass spectrometry. The system not only bridges the gap from discovery imaging to clinical tissue research but also includes key features like Bruker's 10-kHz smartbeam 3D laser, superior imaging detectors, and compatibility with OME-TIFF files through SCiLS Scope software.
Who Are the Key Players In The Immunohistochemistry IHC Market?
Major companies operating in the immunohistochemistry (IHC) market include:
• Thermo Fisher Scientific Inc.
• F. Hoffmann-La Roche AG
• The Merck Group
• Danaher Corporation
• PerkinElmer Inc.
• Bio-Rad Laboratories Inc.
• Cell Signaling Technology Inc.
• Bio SB Inc.
• Agilent Technologies Inc.
• Abcam plc
• Becton Dickinson and Company
• Takara Bio Inc.
• Biocare Medical LLC
• Bio-Genex Laboratories
• Diagnostic BioSystems Inc.
• BioVision Inc.
• PHC Holdings Corporation
• Abbott Laboratories
• Leica Biosystems
• Vector Laboratories
• Indivumed GmbH
• Qritive
• Ionpath Inc.
• Reveal Biosciences
• Akrivis Technologies Private Limited
• LifeSpan BioSciences Inc.
• Enzo Life Sciences Inc.
• Epitomics Inc.
• GenScript Biotech
• Histologix Ltd.
• NeoGenomics Laboratories Inc.
What Are The Regional Insights Into The Immunohistochemistry IHC Market?
North America was the largest region in the immunohistochemistry (IHC) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the immunohistochemistry (IHC) market report during the forecast period. The regions covered in the immunohistochemistry (IHC) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
